【摘要】 目的探讨合贝爽治疗老年不稳定型心绞痛的临床疗效。方法以80例老年不稳定型心绞痛为研究对象,随机双盲分为合贝爽(H)治疗组和异舒吉(I)治疗组。H组合贝爽从100μg/min起始,最大用量300μg/min,持续静滴48h。I组异舒吉2～10mg/h持续静滴6～8h/d。其他基础用药两组相同。观察两组难治性心绞痛、急性心肌梗死、心血管死亡、急诊冠脉介入的发生率。结果H组和I组比较,入院时在年龄、高血压、血脂和血糖等冠心病危险因素差异无统计学意义,难治性心绞痛发生率H组为2例(5.0%),I组为8例(20.0%),差异有统计学意义(P<0.05)。心率和心肌耗氧指数(收缩压×心率)H组比I组明显降低。急性心肌梗死、心血管死亡和急诊冠脉介入发生率两组差异无统计学意义。结论合贝爽治疗老年不稳定型心绞痛疗效显著优于异舒吉。更多还原

【Abstract】 Objective To investigate the efficiency of Herbesser in elderly patients with unstable angina pectoris. Methods 80 elderly patients with unstable angina pectoris were randomly divided into two groups: Group H was given Herbesser and group I was given Isoket. In group H, Herbesser was given intravenously by continuous drip for 48 hours, with the dose from 100 μg/min up to the largest dose of 300 μg/min. In group I, Isoket was given continually with 2-10 mg/h for 6-8 every day. The other treatments were essentially the same in both groups. The incidences of refractory angina, acute myocardial infarction, cardiac death, emergency percutaneous coronary intervention were recorded. Results The two groups, there was no significant difference in the risk factors to coronary disease, such as ages, hypertension, blood lipids, blood glucose and etc. There were 2 cases(5.0%) of refractory angina occurred in group H, while 8 cases(20%) in group I. The difference was significant (P<0.05). There were relatively lower heart rate and myocardial oxygen consumption index (systolic pressure×heart rate) in group H than group I. The incidence of acute myocardial infarction, cardiac death and emergency percutaneous coronary intervention was not significant between the two groups. Conclusion Herbesser is better than Isoket in the treatment of unstable angina in the elderly.更多还原